Search the Newsreel

ANHEUSER-BUSCH INBEV SA/NV – AB InBev Reports Second Quarter and Half Year 2026 Results – Short Form Announcement

Figure 14. Terms and debt repayment schedule as of 30 June 2026 (billion USD) Solid top- and bottom-line performance: Revenue up by 5.6%, Beer volume growth of 1.1% and a 23.4% Underlying EPS increase BRUSSELS, July 30, 2026--(BUSINESS WIRE)--Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): …

2 Reasons AB InBev Stock Is Dropping After Bud Light Brewer’s Earnings Beat

Beer sales volumes are up 1.1% from a year ago, as events like the FIFA World Cup boost sales of Michelob Ultra and other beers. Continue Reading

Canadian Stock Movers for Thursday | Bausch Health Companies Inc Was the Top Gainer; Capital Markets Led Gains

Bausch Health Companies Inc. (BHC.TO) was Thursday's top gainer in Canadian stock markets, rising 12.18% to close at C$7.32. The Capital Markets sector broadly led Thursday's gains, increasing by 2.22%. Trading volume was robust, with 364.57 million shares changing hands, exceeding the 10-day average.

Earnings To Watch: Anheuser-Busch InBev SA/NV (XBRU:ABI) Q2 2026 -- GF Value Sees 16% Downside

Anheuser-Busch InBev SA/NV (XBRU:ABI) is scheduled to release its Q2 2026 earnings on July 30, 2026, with an expected revenue of $14.35 billion and earnings of $1.18 per share. Analyst estimates suggest a full-year 2026 revenue of $56.45 billion and earnings of $4.10 per …

Anheuser-Busch Inbev Q2 Profit Surges, Sees FY26 EBITDA Growth In Line With Mid-term View

(RTTNews) - Belgian drink and brewing major Anheuser-Busch InBev SA/NV (BUD, ABI.BR) on Thursday reported significantly higher profit in its second quarter, mainly as revenues were benefited by higher beer volume. Looking ahead for fiscal 2026, the company expects EBITDA to grow in line …

Bausch Health Companies Inc (BHC) - Tradingkey

This article provides a comprehensive stock analysis of Bausch Health Companies Inc (BHC) by Tradingkey. It highlights the company's stable fundamentals, high growth potential, and current "Hold" rating from analysts with an upside space targeting 7.17. Despite high institutional ownership and a recent shift …

BLCO Q2 2026 Earnings: EPS Surprises to the Upside as Stock Faces Selling Pressure - Short-Term Outlook

Revenue jumps to $31,927M at Anheuser-Busch InBev (NYSE: BUD)

Bausch Health Cos (NYSE:BHC) Sees Large Volume Increase After Earnings Beat

Anheuser-Busch InBev SA/NV 2026 Q2 - Results - Earnings Call Presentation (NYSE:BUD) 2026-07-30

Anheuser-Busch InBev SA/NV reported higher Q2 revenue, earnings, and free cash flow, driven by increased beer volumes and market share gains globally, although performance in China remained challenging. The company saw strong growth in mega brands, non-alcohol beer, and its "Beyond Beer" portfolio, with …

Anheuser-Busch InBev SA/NV (NYSE:BUD) Reaches New 1-Year High After Strong Earnings

Bausch + Lomb (BLCO) Stock Rallies On Margin Gains As Losses Narrow

AB InBev’s no-alcohol beer revenue rises 27% as beer volume grows

AB InBev reported solid second quarter 2026 results with revenue up 5.6% and underlying EPS increasing by 23.4%, driven by strong beer volume growth and strategic investments. The company saw significant growth in its no-alcohol beer portfolio, with revenue up 27%, and its megabrands …

Anheuser-Busch Inbev: Q2 Earnings Snapshot

AB InBev Reports Second Quarter 2026 Results

Figure 14. Terms and debt repayment schedule as of 30 June 2026 (billion USD) Solid top- and bottom-line performance: Revenue up by 5.6%, Beer volume growth of 1.1% and a 23.4% Underlying EPS increase BRUSSELS, July 30, 2026--(BUSINESS WIRE)--Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): …

Bausch Health Cos Q2 Earnings Call Highlights

Key Points Interested in Bausch Health Cos Inc.? Here are five stocks we like better. Bausch Health raised its full-year outlook after reporting strong second-quarter growth: excluding Bausch + Lomb, revenue rose 16% to $1.458 billion and adjusted EBITDA increased 28% to $865 million. …

Bausch Health (BHC) Q2 Earnings and Revenues Beat Estimates

Bausch Health (BHC) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.9 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Premium IOLs Help Propel Strong Q2 as Bausch + Lomb Reports Growth and Raises 2026 Guidance

Bausch + Lomb (NYSE/TSX: BLCO) reported strong second-quarter 2026 financial results, with total revenue increasing by 9 percent to $1.394 billion, driven by double-digit growth in surgical and pharmaceuticals. The company also raised its full-year 2026 revenue guidance. This growth was significantly propelled by …

Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say

Bausch Health (BHC) reported $2.85 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 12.7%. EPS of $1.26 for the same period compares to $0.90 a year ago. The reported revenue represents a surprise of +7.62% over the Zacks …

Bausch & Lomb Earnings: Momentum in Implantables and Pharmaceuticals Shows Off Investment Dividends

Bausch & Lomb reported $1.4 billion in revenue, exceeding FactSet consensus by 2% and showing 9% year-over-year growth, though adjusted EPS of $0.17 was 3% below consensus. Despite the mixed earnings, shares remained flat. The report highlights strong first-half performance, indicating that the company's …

Bausch: Q2 Earnings Snapshot

Bausch + Lomb Upgrades Full-Year Outlook on Strong Second Quarter

Bausch + Lomb has upgraded its full-year outlook following a strong second quarter performance. This positive revision indicates the company's robust financial health and optimistic projections for the remainder of the year.

Bausch & Lomb Corp 2026: Revenue $1.39B, EPS ($0.04) — 10-Q Summary

Bausch & Lomb Corp (BLCO) reported strong second-quarter 2026 results with revenue reaching $1.39 billion, an increase driven by pricing and volume gains across segments. The company significantly reduced its net loss compared to the prior year, with diluted loss per share narrowing to …

BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE

Second Quarter Consolidated Revenues of $2.85 billion, up 13% on a Reported basis and 11% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Income Attributable to Bausch Health of $258 million and GAAP Net Income of $260 million GAAP Earnings …

Bausch & Lomb Corp (BLCO) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ...

This article first appeared on GuruFocus. Release Date: July 29, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Bausch & Lomb Corp (NYSE:BLCO) reported 8% constant currency revenue growth, showcasing consistent performance across …

Bausch Health earnings up next as analysts eye profit surge

Bausch Health Companies Inc. is set to report second-quarter earnings, with analysts anticipating a significant profit surge. The company is expected to post earnings of $1.01 per share on revenue of $2.67 billion, driven by improving operating leverage and strategic initiatives like international expansion. …

AB INBEV : UBS reiterates its Buy rating

UBS has re-affirmed its Buy rating for AB InBev with a target price of EUR 88. This positive outlook from Sanjeet Aujla at UBS was published on July 29, 2026. The article highlights recent analyst activities for Anheuser-Busch InBev SA/NV, including other recent Buy …

Bausch + Lomb Corporation Raises Earnings Guidance for the Full Fiscal Year 2026

Bausch + Lomb Corporation has updated its earnings guidance for the full fiscal year 2026, raising its revenue expectations. The company now anticipates revenue to fall between $5.440 billion and $5.540 billion, an increase from its previous forecast of $5.420 billion to $5.520 billion.

Bausch + Lomb (BLCO) Q2 Earnings Meet Estimates

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.16 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was …

Earnings Flash (BLCO) Bausch + Lomb Corporation Posts Q2 Adjusted EPS $0.15 per Share, Vs. FactSet Est of $0.15

Bausch + Lomb Corporation (BLCO) announced its Q2 adjusted earnings per share (EPS) of $0.15, meeting FactSet's estimate. This financial report provides key insights into the company's performance for the second quarter.

Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance

Revenue of $1.394 Billion Revenue Grew 9% as Reported and 8% on a Constant Currency1 Basis Compared to the Second Quarter of 2025 GAAP Net Loss Attributable to Bausch + Lomb Corporation of $14 Million Adjusted EBITDA (non-GAAP)1 of $241 Million; Adjusted EBITDA Excluding …

Sei Investments Co. Has $25.72 Million Position in Anheuser-Busch InBev SA/NV $BUD

Sei Investments Co. increased its stake in Anheuser-Busch InBev SA/NV by 24% in the first quarter, now holding 370,795 shares valued at $25.72 million. Several other hedge funds also adjusted their positions in the consumer goods maker. Anheuser-Busch InBev SA/NV (NYSE:BUD) stock is currently …

Bausch Health Cos (NYSE:BHC) Posts Quarterly Earnings Results, Beats Expectations By $0.30 EPS

NuScale Power (SMR) Expected to Announce Earnings on Wednesday

Bausch Health (NYSE: BHC) boosts 2026 guidance on strong Q2 2026 results

Anheuser-Busch InBev SA/NV (BUD) Earnings Date and Reports 2026 $BUD